放疗联合安罗替尼对小细胞肺癌患者胱天蛋白酶3、多腺苷二磷酸核糖聚合酶表达的影响研究

目的探讨放疗联合安罗替尼对小细胞肺癌(SCLC)患者胱天蛋白酶3(caspase 3)、多腺苷二磷酸核糖聚合酶(PARP)表达的影响。方法将86例SCLC患者随机分为放疗组(n=42)和联合组(放疗联合安罗替尼,n=44),探索两组1年生存率、不良反应发生情况及对caspase 3、PARP表达的影响。结果治疗前两组患者血清caspase 3、PARP水平比较,差异均无统计学意义(P﹥0.05);治疗后联合组患者血清caspase 3水平明显高于放疗组,PARP水平明显低于放疗组,差异均有统计学意义(P﹤0.01)。两组患者白细胞减少、中性粒细胞减少发生率比较,差异均无统计学意义(P﹥0.05)。联合组患者1年生存率高于放疗组,差异有统计学意义(P﹤0.05)。结论放疗联合安罗替尼可以有效提高SCLC患者血清内caspase 3水平,降低PARP水平,延长患者的生存时间,值得临床进一步研究。

Effects of radiotherapy combined with anlotinib on the expression of caspase 3 and poly(ADP-ribose)polymerase in patients with small cell lung cancer

Objective To investigate the effect of radiotherapy combined with anlotinib on the expression of caspase 3 and poly(ADP-ribose)polymerase(PARP)in patients with small cell lung cancer(SCLC).Method Altogether,86 patients with SCLC were randomized into radiotherapy group(n=42)and combination therapy group(radiotherapy combined with anlotinib,n=44),respectively,the 1-year survival rate,incidence of adverse reactions,and the effects on caspase 3 and PARP expression were evaluated for all patients and compared between the two groups.Result The serum caspase 3 and PARP levels were similar in both groups before treatment(P>0.05);while after treatment,the caspase 3 level was significantly higher in combination group than in radiotherapy group,and PARP level was lower instead(P<0.01).No significant difference was found between the two groups in terms of the incidence of leukocytopenia and neutropenia(P>0.05).The combination therapy group patients had significantly higher 1-year survival rate versus those in radiotherapy group(P<0.05).Conclusion Combination of radiotherapy and anlotinib effectively improves the level of caspase 3 in serum of SCLC patients,and reduces the level of PARP,with additional benefits of extended survival time.